This announcement is a separate document:
金陵药业：金陵药业股份有限公司监事会关于公司调整2023年度向特定对象发行A股股票相关事项的书面审核意见
Jinling Pharmaceutical: Written review opinion of the board of supervisors of Jinling Pharmaceutical Co., Ltd. on matters relating to the company's adjustment to issue A-shares to specific targets in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.